Search Results

There are 21607 results for: content related to: Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?

  1. Monoamine oxidase B inhibitors for early Parkinson's disease

    Intervention Review

    The Cochrane Library

    Kristian Turnbull, Robert Caslake, Angus Macleod, Natalie Ives, Rebecca Stowe and Carl Counsell

    Published Online : 20 JUL 2005, DOI: 10.1002/14651858.CD004898.pub2

  2. Pharmacokinetics and Absolute Bioavailability of Selegiline Following Treatment of Healthy Subjects With the Selegiline Transdermal System (6 mg/24 h): A Comparison With Oral Selegiline Capsules

    The Journal of Clinical Pharmacology

    Volume 47, Issue 10, October 2007, Pages: 1256–1267, Dr Albert J. Azzaro, Dr John Ziemniak, Ms Eva Kemper, Dr Bryan J. Campbell and Dr Chad VanDenBerg

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007304779

  3. You have free access to this content
    Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids

    British Journal of Clinical Pharmacology

    Volume 47, Issue 3, March 1999, Pages: 249–254, Kari Laine, Markku Anttila, Antti Helminen, Hari Karnani and Risto Huupponen

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.1999.00891.x

  4. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

    Movement Disorders

    Volume 26, Issue S3, October 2011, Pages: S2–S41, Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz and Cristina Sampaio

    Version of Record online : 21 OCT 2011, DOI: 10.1002/mds.23829

  5. You have free access to this content
    Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline

    British Journal of Pharmacology

    Volume 143, Issue 3, October 2004, Pages: 371–378, Zaid A Abassi, Ofer Binah and Moussa B H Youdim

    Version of Record online : 17 FEB 2009, DOI: 10.1038/sj.bjp.0705962

  6. Selegiline for Alzheimer's disease

    Intervention Review

    The Cochrane Library

    Jacqueline Birks and Leon Flicker

    Published Online : 20 JAN 2003, DOI: 10.1002/14651858.CD000442

  7. Selegiline Transdermal System: An Examination of the Potential for CYP450-Dependent Pharmacokinetic Interactions With 3 Psychotropic Medications

    The Journal of Clinical Pharmacology

    Volume 47, Issue 2, February 2007, Pages: 146–158, Dr Albert J. Azzaro, Dr John Ziemniak, Ms Eva Kemper, Dr Bryan J. Campbell and Dr Chad VanDenBerg

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270006296151

  8. Neuroprotection in Parkinson's disease: Clinical trials

    Annals of Neurology

    Volume 53, Issue S3, 2003, Pages: S87–S99, Fabrizio Stocchi and C. Warren Olanow

    Version of Record online : 24 MAR 2003, DOI: 10.1002/ana.10488

  9. You have free access to this content
    Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat

    British Journal of Pharmacology

    Volume 149, Issue 6, November 2006, Pages: 647–656, J P M Finberg, A Gross, O Bar-Am, R Friedman, Y Loboda and M B H Youdim

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0706908

  10. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study

    Movement Disorders

    Volume 19, Issue 4, April 2004, Pages: 426–432, Cheryl H. Waters, Kapil D. Sethi, Robert A. Hauser, Eric Molho and John M. Bertoni

    Version of Record online : 10 FEB 2004, DOI: 10.1002/mds.20036

  11. Marked Effect of Liver and Kidney Function on the Pharmacokinetics of Selegiline

    Clinical Pharmacology & Therapeutics

    Volume 77, Issue 1, January 2005, Pages: 54–62, Markku Anttila, Eero A. Sotaniemi, Olavi Pelkonen and Arja Rautio

    Version of Record online : 16 JAN 2005, DOI: 10.1016/j.clpt.2004.09.004

  12. Parkinson's Disease

    Standard Article

    Wiley Handbook of Current and Emerging Drug Therapies

    Published Online : 13 OCT 2006, DOI: 10.1002/9780470041000.cedt084

  13. You have free access to this content
    Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo

    British Journal of Pharmacology

    Volume 126, Issue 4, February 1999, Pages: 997–1002, Itschak Lamensdorf, Shai Porat, Rabi Simantov and John P M Finberg

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0702389

  14. You have free access to this content
    Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease

    British Journal of Clinical Pharmacology

    Volume 74, Issue 2, August 2012, Pages: 284–295, Thuy C. Vu, John G. Nutt and Nicholas H. G. Holford

    Version of Record online : 10 JUL 2012, DOI: 10.1111/j.1365-2125.2012.04208.x

  15. Changes in vascular alpha1- and alpha2-adrenoceptor responsiveness by selegiline treatment

    Fundamental & Clinical Pharmacology

    Volume 15, Issue 4, August 2001, Pages: 239–245, M. Pelat, P. Verwaerde, M. A. Tran, M. Berlan, J. M. Senard and J. L. Montastruc

    Version of Record online : 7 JUL 2008, DOI: 10.1046/j.1472-8206.2001.00036.x

  16. You have free access to this content
    Neuroprotective actions of selegiline

    Journal of Neuroscience Research

    Volume 67, Issue 3, 1 February 2002, Pages: 285–289, M. Ebadi, S. Sharma, S. Shavali and H. El Refaey

    Version of Record online : 7 JAN 2002, DOI: 10.1002/jnr.10148

  17. You have free access to this content
    Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration

    Journal of Neurochemistry

    Volume 105, Issue 5, June 2008, Pages: 1970–1978, Wen Zhu, Wenjie Xie, Tianhong Pan, Joseph Jankovic, Jun Li, Moussa B. H. Youdim and Weidong Le

    Version of Record online : 8 MAR 2008, DOI: 10.1111/j.1471-4159.2008.05330.x

  18. Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?

    Movement Disorders

    Volume 26, Issue 7, June 2011, Pages: 1187–1193, Carl E. Clarke, Smitaa Patel, Natalie Ives, Caroline Rick, Keith Wheatley and Richard Gray

    Version of Record online : 14 APR 2011, DOI: 10.1002/mds.23519

  19. Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease

    The Journal of Clinical Pharmacology

    Volume 45, Issue 8, August 2005, Pages: 878–894, Dr Jack J. Chen and Dr David M. Swope

    Version of Record online : 19 MAR 2013, DOI: 10.1177/0091270005277935

  20. You have free access to this content
    Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man

    British Journal of Clinical Pharmacology

    Volume 45, Issue 6, June 1998, Pages: 551–558, P. Bitsios, R. W. Langley, S Tavernor, K. Pyykkö, M. Scheinin, E. Szabadi and C. M. Bradshaw

    Version of Record online : 4 JAN 2002, DOI: 10.1046/j.1365-2125.1998.00729.x